Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHA:603707)
8.40
-0.13 (-1.52%)
May 20, 2026, 11:29 AM CST
SHA:603707 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 585.83 | 581.54 | 826.14 | -189.45 | 1,091 | 1,059 |
Depreciation & Amortization | 242.98 | 242.98 | 174.85 | 154.06 | 139.53 | 93.22 |
Other Amortization | 0.13 | 0.13 | 0.19 | 0.19 | 0.19 | 0.2 |
Loss (Gain) From Sale of Assets | 3.26 | 3.26 | 0.04 | 0.04 | 0.11 | 1.03 |
Asset Writedown & Restructuring Costs | -221.53 | -221.53 | 8.64 | 0.03 | 10.22 | 7.23 |
Loss (Gain) From Sale of Investments | -28.12 | -28.12 | -7.81 | 85.58 | -24.1 | -24.57 |
Provision & Write-off of Bad Debts | 2.77 | 2.77 | 8.22 | -3.05 | -0.42 | 3.22 |
Other Operating Activities | 434.88 | 93.32 | -34.84 | 1,241 | -99.43 | 87.47 |
Change in Accounts Receivable | -321.33 | -321.33 | -13.19 | 163.36 | -1,456 | -148.2 |
Change in Inventory | 591.79 | 591.79 | 598.72 | 213.28 | -731.57 | -444.05 |
Change in Accounts Payable | - | - | -185.77 | 224.66 | 1,710 | 46.82 |
Change in Other Net Operating Assets | 159.21 | 159.21 | -20.08 | -21.25 | -15.1 | 13.45 |
Operating Cash Flow | 1,529 | 1,183 | 1,501 | 1,619 | 595.45 | 683.63 |
Operating Cash Flow Growth | 4.38% | -21.21% | -7.28% | 171.92% | -12.90% | - |
Capital Expenditures | -389.38 | -560.15 | -506.82 | -419.07 | -470.08 | -440.76 |
Sale of Property, Plant & Equipment | 0.04 | 0.04 | 0 | 0.15 | 0.11 | 0.54 |
Cash Acquisitions | 0.72 | - | - | - | - | -13.87 |
Investment in Securities | -557.16 | -226.41 | -459.05 | -757.47 | 36.06 | 610.72 |
Other Investing Activities | 22.15 | 28.12 | 55.14 | 14.34 | 33.42 | 13.51 |
Investing Cash Flow | -923.63 | -758.41 | -910.73 | -1,162 | -400.5 | 170.14 |
Long-Term Debt Issued | - | 2,179 | 1,866 | 3,399 | 3,358 | 2,126 |
Total Debt Issued | 3,001 | 2,179 | 1,866 | 3,399 | 3,358 | 2,126 |
Long-Term Debt Repaid | - | -1,986 | -2,373 | -3,094 | -3,441 | -2,687 |
Total Debt Repaid | -1,722 | -1,986 | -2,373 | -3,094 | -3,441 | -2,687 |
Net Debt Issued (Repaid) | 1,279 | 192.84 | -506.04 | 305.39 | -83.41 | -560.94 |
Issuance of Common Stock | - | - | - | - | 0.37 | 41.17 |
Repurchase of Common Stock | -0.54 | - | -12.04 | -5.72 | -1.13 | -0.87 |
Common Dividends Paid | -214.85 | -218.42 | -213.19 | -248.47 | -226.65 | -191.75 |
Other Financing Activities | -29.11 | -29.11 | - | - | - | -200 |
Financing Cash Flow | 1,034 | -54.69 | -731.28 | 51.2 | -310.81 | -912.39 |
Foreign Exchange Rate Adjustments | -32.48 | -10.59 | -16.7 | 83.18 | -16.11 | 20.05 |
Net Cash Flow | 1,607 | 359.11 | -157.49 | 591.51 | -131.97 | -38.57 |
Free Cash Flow | 1,139 | 622.64 | 994.41 | 1,200 | 125.37 | 242.87 |
Free Cash Flow Growth | 42.64% | -37.39% | -17.14% | 857.27% | -48.38% | - |
Free Cash Flow Margin | 28.24% | 15.60% | 25.34% | 30.53% | 3.38% | 6.59% |
Free Cash Flow Per Share | 0.70 | 0.39 | 0.60 | 0.76 | 0.08 | 0.15 |
Cash Income Tax Paid | 66.98 | - | 104.54 | 108.86 | 91.01 | 46.06 |
Levered Free Cash Flow | 667.99 | 282.67 | 498.14 | 1,279 | -540.91 | -186.72 |
Unlevered Free Cash Flow | 702.52 | 317.2 | 545.43 | 1,330 | -504.75 | -129.08 |
Change in Working Capital | 508.43 | 508.43 | 525.78 | 330.47 | -521.49 | -543.45 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.